MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.

Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.

JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia.

Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia.

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

Practical management of classical myeloproliferative disorder patients: a clinician's guide.

Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic.

Estrogen-based hormone therapy and thrombosis risk in women with essential thrombocythemia.

Microcytosis in agnogenic myeloid metaplasia: prevalence and clinical correlates.